DexCom Price to Free Cash Flow Ratio 2010-2024 | DXCM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

DexCom average price to free cash flow ratio for 2024 was 12.72, a 28.46% decline from 2023.
DexCom average price to free cash flow ratio for 2023 was 17.78, a 13.54% decline from 2022.
DexCom average price to free cash flow ratio for 2022 was 15.66, a 94.23% increase from 2021.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

DexCom average price to free cash flow ratio for 2024 was 12.72, a 28.46% decline from 2023.
DexCom average price to free cash flow ratio for 2023 was 17.78, a 13.54% decline from 2022.
DexCom average price to free cash flow ratio for 2022 was 15.66, a 94.23% increase from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$217.3B
Intuitive Surgical (ISRG)	$204B
Alcon (ALC)	$45.1B
Edwards Lifesciences (EW)	$42B
IQVIA Holdings (IQV)	$35.9B
IDEXX Laboratories (IDXX)	$34.3B
Waters (WAT)	$24B
STERIS (STE)	$21.7B
SONOVA HOLDING (SONVY)	$20.8B
Hologic (HOLX)	$16.1B
Fresenius Medical Care AG KGaA (FMS)	$14.6B
Globus Medical (GMED)	$12.6B
Sysmex ADR (SSMXY)	$12.2B
Penumbra (PEN)	$10.4B
Masimo (MASI)	$9.5B
Glaukos (GKOS)	$8.8B
Teleflex (TFX)	$8.4B
Integer Holdings (ITGR)	$4.8B
Inari Medical (NARI)	$4.7B
PROCEPT BioRobotics (PRCT)	$3.8B
Veracyte (VCYT)	$3.4B
LivaNova (LIVN)	$2.8B
Nihon Kohden (NHNKY)	$2.6B
Tandem Diabetes Care (TNDM)	$2.4B
Elekta AB (EKTAY)	$2.3B
TransMedics (TMDX)	$2.2B
Integra LifeSciences Holdings (IART)	$2B
Alphatec Holdings (ATEC)	$1.7B
Artivion (AORT)	$1.3B
RxSight (RXST)	$1.3B